BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Inclusion Criteria: * Expected survival \> 12 weeks * Diagnosis of Multiple Myeloma by MWG criteria 20 * Patients previously received at least 3 different prior treatment regimens for multiple myeloma, including alkylating agent, protein inhibitors, and immunomodulator, and have disease progression in the past 60 days * Important organs function enough to tolerate this therapy * At least 90 days after stem cell transplantation * Accessible to intravenous injection, and no white blood cell collection contraindications * Sexually active patients must be willing to utilize one of the more effective birth control methods for 30 days after the CTL infusion. Male partner should use a condom * Able to understand and sign the Informed Consent Document. Exclusion Criteria: * Patients with symptoms of central nervous system * Patients with second malignancies in addition to multiple myeloma * Active hepatitis B or C, HIV infections * Any other active diseases could affect the enrollment of this trial * Suffering severe cardiovascular or respiratory disease * Poorly controlled hypertension * Long term use of immunosuppressive agents after organ transplantation, except currently receiving or recently received glucocorticoid treatment * A history of mental illness and poorly controlled * Screening showing target cell transduction efficacy is lower than 30%, or T cell proliferation is not enough for infusion (less than 5 fold) * Occurrence of unstable pulmonary embolism, deep vein thrombosis, or other major arterial/venous thromboembolic events 30 days prior to assignment * Women of child-bearing potential who are pregnant or breastfeeding during therapy, or have a planned pregnancy with 2 months after therapy * Women of child-bearing potential who are not willing to practice birth control from the time of enrollment on this study and for 2 months after receiving the preparative regimen. Women of child bearing potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion * Active systemic infections or uncontrolled infection within 14 days prior enrollment * Subjects suffering disease affects the understanding of informed consent or complying with study protocol.